EGFR and nasopharyngeal carcinoma: By following conventional practice focusing on targetable mutations identification, we performed genomics sequencing for tumors of individual patients, but unfortunately, well-known drug sensitizing hotspot mutations were seldom found in the majority of NPC tumors as expected51, for example, the frequency of EGFR SNVs was only 0.94% (1/106) in our NPC cohort (Supplementary Data 3), which kept us from directly identifying corresponding targeted drugs.